|
News Press Releases and Articles Calendar of Events How to Help Gates Foundation Grant to GAELF The Global Alliance Global Alliance History Goals Global Alliance Structure Executive Group Partnerships GAELF Logo LF Webring About LF What is LF? How is LF Contracted? How is LF Diagnosed? Prevent/Eliminate LF Manage LF LF and Children Additional Treatment Benefits LF Slideshow In Depth Disease Info Where is LF? Countries and Map List Moving Forward Starting Out Success Stories Progress and Plans Elimination Strategy Operational Research Progress to Date Economics of LF Return on Investment The Way Ahead Highlighted Programmes Burkina Faso Sri Lanka For the Media Press Release Archive Press Kits Photos Articles Video Clips Media Contacts FAQs Publications LF News Annual Reports General Publications Training Material Videos Journal Articles & Other Pubs EG Updates Gates Foundation |
![]() |
| Diagnosis
Until recently, diagnosis of filarial infection depended on the direct demonstration of the parasite (almost always microfilariae) in blood using relatively cumbersome techniques and having to take into account the periodicity (nocturnal or diurnal) of microfilariae. Alternative methods based on detection of antibodies by immunodiagnostic tests did not prove satisfactory since they both failed to distinguish between active and past infections and had problems with specificity owing to their cross-reactivity with common gastrointestinal parasites and other organisms. Antigen detection:
Circulating filarial antigen (CFA) detection should now be regarded as
the 'gold standard' for diagnosing Wuchereria bancrofti infections.
The specificity of these assays is excellent, and the sensitivity is greater
than that achievable by the earlier parasite-detection assays. Essentially
all individuals with microfilaraemia also have detectable circulating
antigen, as well as do a proportion of those amicrofilaraemic individuals
with clinical manifestations of filariasis (e.g., lymphoedema or elephantiasis)
but no circulating microfilariae. In addition, some individuals who appear
normal also have detectable circulating antigen that disappears after
effective treatment with DEC for these cryptic infections. Two commercial
configurations of this assay are available, one based on ELISA methodology
that yields semi-quantitative results, and the other based on a simple
card (immunochromatographic) test, yielding only qualitative (positive/negative)
answers. Thus, this new diagnostic approach is equally applicable to clinical
or field evaluation of bancroftian filariasis infections. Unfortunately,
no such test is currently available for brugian filariasis. |
|
|
© Global Alliance to Eliminate Lymphatic Filariasis |